120 related articles for article (PubMed ID: 28687745)
1. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.
Bianconi D; Heller G; Spies D; Herac M; Gleiss A; Liebmann-Reindl S; Unseld M; Kieler M; Scheithauer W; Streubel B; Zielinski CC; Prager GW
Sci Rep; 2017 Jul; 7(1):4851. PubMed ID: 28687745
[TBL] [Abstract][Full Text] [Related]
2. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
3. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
Braun LM; Lagies S; Guenzle J; Fichtner-Feigl S; Wittel UA; Kammerer B
Cells; 2020 May; 9(5):. PubMed ID: 32438599
[TBL] [Abstract][Full Text] [Related]
5. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
8. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Lu J; Wu H; Wang L; Liang X; Liang Z; Liu T
Diagn Pathol; 2017 May; 12(1):42. PubMed ID: 28558797
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
Al-Batran SE; Geissler M; Seufferlein T; Oettle H
Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Ramfidis VS; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):344-6. PubMed ID: 23846924
[TBL] [Abstract][Full Text] [Related]
14. The winning formulation: the development of paclitaxel in pancreatic cancer.
Ma WW; Hidalgo M
Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
16. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.
Yu KH; Ozer M; Cockrum P; Surinach A; Wang S; Chu BC
Cancer Med; 2021 Dec; 10(24):8934-8943. PubMed ID: 34811961
[TBL] [Abstract][Full Text] [Related]
17. [Nab-paclitaxel].
Lopez-Trabada Ataz D; Dumont S; André T
Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
[TBL] [Abstract][Full Text] [Related]
18. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
Neesse A; Michl P; Tuveson DA; Ellenrieder V
Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Taxane-Pretreated Metastatic Gastric Cancer with Excellent Response to Nab-Paclitaxel].
Kawabata R; Kimura Y; Kawase T; Yoshikawa M; Kameda C; Matsumura T; Koga C; Murakami M; Hirota M; Noura S; Ikenaga M; Shimizu J; Hasegawa J
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2088-90. PubMed ID: 26805273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
